欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (8): 916-919.

• 药物治疗学 • 上一篇    下一篇

长春瑞滨联合多西他赛治疗晚期非小细胞肺癌的临床研究

鲍志坚1, 陈道宝2, 李柏颖1   

  1. 1 浙江省中西医结合医院呼吸内科,杭州 310003,浙江;
    2 浙江省肿瘤医院乳腺神经骨软肿瘤外科, 杭州 310022,浙江
  • 收稿日期:2013-12-18 修回日期:2014-07-08 出版日期:2014-08-26 发布日期:2014-08-26
  • 作者简介:鲍志坚,男,硕士,副主任医师,主要从事哮喘、COPD、感染及肺癌等临床治疗与研究相关工作。 Tel: 13588819145 E-mail: baozhijian633@163.com

Research on the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on non-small cell lung cancer

BAO Zhi-jian1, CHEN Dao-bao2, LI Bo-ying1   

  1. 1 Respiratory Medicine,Integrative Medicine Hospital of Zhejiang Province,Hangzhou 310003, Zhejiang, China;
    2 Mammary Neurological Soft Bone Tumor Surgery, Zhejiang Cancer Hospital,Hangzhou 310022, Zhejiang,China
  • Received:2013-12-18 Revised:2014-07-08 Online:2014-08-26 Published:2014-08-26

摘要: 目的 评价长春瑞滨(NVB)联合多西他赛(TXT)治疗晚期非小细胞肺癌疗效及不良反应并证明两药联用是否具有协同作用。方法 53例晚期非小细胞肺癌(NSCLC)患者,其中男性34例,女性19例,所有患者年龄均在60岁以上。其中长春瑞滨单药治疗组(单药组)26例,给予长春瑞滨 25 mg/m2,第1、8天给药,每21天为1个周期,2个周期为一疗程;长春瑞滨联合多西他赛治疗组(联合组)27例,长春瑞滨 25 mg/m2,第1、8天给药,多西他赛 75 mg/m2,在给药前1天开始口服地塞米松 8 mg,每天2次,连续 3 d。结果 单药组完全缓解(CR)、部分缓解(PR)、稳定(SD)、进展(PD)、总控制率和1年生存率分别为0%(0/26),30.77%(8/26),53.85%(14/26),15.38%(4/26),84.6%(22/26)和 42.31%(11/26);联合组CR、PR、SD、PD,总控制率和1年生存率分别为 3.70%(1/27),33.33%(9/27),51.85%(14/27),11.11%(3/27),88.9%(24/27)和 51.85%(14/27),两组之间无统计学差异。不良反应以骨髓抑制、消化道反应、脱发、肌肉酸痛为主,两者之间比较差异具有统计学意义(P<0.05)。结论 长春瑞滨联合多西他赛治疗晚期非小细胞肺癌与长春瑞滨单药治疗疗效无显著差别,但与多西他赛联用后不良反应增多,部分器官功能衰退的患者难以承受,应予以重视。

关键词: 长春瑞滨, 多西他赛, 非小细胞肺癌

Abstract: AIM: To evaluate the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on NSCLC , and to prove the synergistic effect of combination chemotherapy. METHODS: A total of 53 NSCLC patients were randomized into 2 groups, 26 cases of them were treated with NVB at the dose of 25 mg/m2 on d 1, d 8, every 21 days. 27 cases of them were treated with NVB at the dose of 25 mg/m2 on d1, d8, every 21 days and TXT were administered 75 mg/m2 by infusion, with a 3-day pre-medication of corticosteroids b.i.d to reduce the incidence of severe fluid retention and hypersensitivity. RESULTS: NVB group CR, PR, SD, PD, TCR and 1-year survival rate was 0%(0/26), 30.77% (8/26), 53.85%(14/26), 15.38%(4/26), 84.6%(22/26)and 42.31%(11/26). The NVB and TXT group CR, PR, SD, PD, TCR and 1-year survival rate was 3.70%(1/27), 33.33%(9/27), 51.85%(14/27), 11.11%(3/27), 88.9%(24/27) and 51.85% (14/27). There was no statistical significance in the two groups, the common adverse event were bone marrow suppression. There was statistical significance in different two groups (P<0.05). CONCLUSION: Although the effective of combination chemotherapy with NVB and TXT may be a little better than the single NVB,the adverse reactions is more serious.

Key words: NVB, TXT, non-small cell lung cancer

中图分类号: